Our Purpose
Serving Science
Nucleus Biologics, The Cell Performance Company™, is focused on providing premium quality products and a superior cell culture experience for our customers. We understand how important cell culture is to the success of life science research. These cells are what enable the scientific breakthroughs that extend and save lives. Your ability to generate quality data is dependent upon using tested, proven products.
A trusted source for precision cell culture solutions that feed scientific breakthrough.
Curing disease starts with science
In a perfect world, all scientific experiments move forward without confounding variables. While perfection isn’t possible, mitigating risk by demanding only the highest quality cell culture products will facilitate scientific breakthroughs. Working together, we can speed up discovery and cure disease by ensuring that our products meet the demanding requirements of those fueling today’s increasingly complex scientific innovations.
At the core of cell science
We are elevating consistency and authenticity in cell culture. We believe we can accomplish this by delivering superior products through a transparent, consistent and proven supply chain that eliminates variability for you, our customers.
“For us to realize our mission of speeding the time from discovery to cure we must be unrelenting in the pursuit of innovation of product and process.”
– Chief Executive Officer, David Sheehan
David Sheehan
President, CEO, Director
Dave was previously at Volcano Corporation a publicly held life sciences company that was sold to Philips for $1.2 Billion. Dave held various roles including the COO, EVP Global Operations and General Manager Volcano Japan, and President of several business units. Prior to Volcano, Dave was the President and CEO of Digirad a medical imaging company he took public in 2004. Prior to that, Dave worked at Baxter and Haemonetics. He has extensive experience in product creation, manufacturing scale up, managing growth and organization development. Dave earned a BSME with Distinction from WPI and an MBA from The Amos Tuck School at Dartmouth College.
Dr. Alyssa Master
Senior VP of Operations
Dr. Alyssa Master has ten years of laboratory research experience including five years as a lab manager prior to joining Nucleus Biologics. As a biomaterials engineer, her area of expertise is in the field of nanoparticle-mediated drug delivery, particularly for the delivery of cancer therapeutics. In graduate school, Alyssa was the recipient of both the Medtronic Fellowship and the NIH Ruth L. Kirschstein Predoctoral Fellowship. During these fellowships, Alyssa developed a novel targeted drug delivery platform for intravenous delivery of photodynamic therapy agents. Following graduate school, Alyssa completed a postdoctoral fellowship in the Department of Pharmacology at the University of Illinois at Chicago Medical School and a postdoctoral fellowship in the Division of Molecular Pharmaceutics at the University of North Carolina at Chapel Hill School of Pharmacy. Alyssa has a PhD in Biomedical Engineering from Case Western Reserve University.
Will Ater
CFO
Will has over 30 years of experience in financial and business leadership roles across a diverse range of industries in wireless technologies, internet of things devices, and cosmeceuticals. Prior to joining Nucleus, Will was the Sr. VP of Finance and Operations for SENTE, Inc. and before that was the CFO of LocusTraxx, Inc. leading the company to a successful acquisition exit. Will also spent 12 years at Qualcomm, Inc. in various leadership roles across multiple divisions including new business development, finance lead for the successful acquisition of a business from Alcatel and leading international finance and business operations for Qualcomm’s Omnitracs division. Will has a BS degree in accounting from Purdue University and an MBA in Finance with honors from the University of North Texas.
Dr. Asma Ayari
R&D Manager
Dr. Asma Ayari was most recently head of our Formulation Services group and has extensive experience in media analysis, testing and formulation for Cell and Gene Therapy. Asma did her PhD work in virology and immunology and brings a deep understanding of how complex cellular systems are affected by small changes in the chemical composition of the microenvironment. Dr. Ayari holds a M.S. in Microbiology from University of Tunis and a Ph.D. in Virology, Immunology and Metabolism from Universite de Lille in France.
Dr. Michael Morgan
VP of Sales
Mike Morgan, PhD has been supporting biotherapeutic and research markets for 26 years through customer-education and business-development channels. He’s held leadership roles in marketing and sales, including membrane technology and immunoassay companies, most recently supporting, selling, and evangelizing virus-removal filters for 19 years with Asahi Kasei Bioprocess. Dr. Morgan received a double degree, Biochemistry and Writing, from the University of New Hampshire, and segued to earning his PhD in Biochemistry at Brandeis University. In his current role, he hopes to leverage his experiences in the biotherapeutic ecosystem to enable customers to optimize cell performance and speed the process from discovery to therapies.
Dr. Brad Taylor
VP of Marketing
Dr. Brad Taylor has 17 years of experience commercializing products for scientists in both academia and industry prior to joining Nucleus Biologics. He was most recently Director of Global Marketing at HemaCare, Corp. supporting the needs of the cellular therapy industry. He spent 11 years at PerkinElmer, Inc. supporting in vivo imaging platforms and has held leadership roles in technical support, product management and marketing. Dr. Taylor holds a M.S. in Microbiology and Immunology from Louisiana State University Health Sciences Center and a Ph.D. in Molecular Biology and Genetics from Friedrich-Alexander University in Germany.
Alexandra (Ally) Silverton, MD, MPH
Director
Ally is an assistant professor at University of Central Florida and a board-certified Internal Medicine Physician. She also serves as Medical Director for Tavistock Development Company in Lake Nona’s Health and Life Sciences cluster. Before joining Tavistock in 2019, Ally worked as an assistant professor and an academic hospitalist at both Tulane University and Emory University.
Ally received her Bachelor of Science Degree in Biology from Duke University and her MD from Emory University School of Medicine. She also holds a Master’s degree in Public Health from the Rollins School of Public Health at Emory University. Ally completed her Internal Medicine residency at New York University (NYU).
Shehan Dissanayake, PhD
Chairman of the Board
Shehan is a senior Managing Director and member of the Board of Directors of the Tavistock Group, a privately held investment company. Before joining Tavistock Group in 2002, Shehan was a Managing Partner of Arthur Andersen.
He holds a Ph.D. in Pharmacological and Physiological Sciences from The University of Chicago.
Kieran T. Gallahue
Director
Kieran was Chairman of the Board and Chief Executive Officer of CareFusion Corporation from 2011 until March 2015 when it was sold to Becton Dickinson. Previously, Kieran joined ResMed, Inc. in 2003 as President and Chief Operating Officer of the Americas, was promoted to the role of President and Chief Operating Officer of ResMed Global in 2004, and Chief Executive Officer and director in 2008. Kieran also served on the board of Volcano Corporation until 2015. Prior to 2002, he held various marketing, sales and financial positions within Nanogen, Inc., Instrumentation Laboratory, the Procter & Gamble Company, and the General Electric Company. Kieran currently sits on the board of directors of Edwards Lifesciences and Arena Pharmaceuticals.
Kieran has a bachelor’s degree from the Rutgers University College of Agricultural and Biological Sciences and an MBA from Harvard Business School.
Neil Reisman
Director
Neil Reisman has more than 30 years of business experience with emphasis on operations, legal, tax, investments and finance. He has worked with the biopharmaceutical industry since 2004. In addition, he has worked at various multinational companies, including Tavistock Group, Arthur Andersen and Amoco Corporation. He received his juris doctor from the University of Pennsylvania Law School and his Bachelor of Science in Accountancy from the University of Illinois.
David Sheehan
President, CEO, Director
Dave was previously at Volcano Corporation a publicly held life sciences company that was sold to Philips for $1.2 Billion. Dave held various roles including the COO, EVP Global Operations and General Manager Volcano Japan, and President of several business units. Prior to Volcano, Dave was the President and CEO of Digirad a medical imaging company he took public in 2004. Prior to that, Dave worked at Baxter and Haemonetics. He has extensive experience in product creation, manufacturing scale up, managing growth and organization development. Dave earned a BSME with Distinction from WPI and an MBA from The Amos Tuck School at Dartmouth College.